The Enterprise Value as of September 2024 (TTM) for Tempest Therapeutics, Inc. (TPST) is 23.16M

According to Tempest Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 23.16M. This represents a change of -60.86% compared to the average of 59.17M of the last 4 quarters.

Tempest Therapeutics, Inc. (TPST) Historical Enterprise Value (quarterly & annually)

How has TPST Enterprise Value performed in the past?

The mean historical Enterprise Value of Tempest Therapeutics, Inc. over the last ten years is 120.27M. The current 23.16M Enterprise Value has changed 1.83% with respect to the historical average. Over the past ten years (40 quarters), TPST's Enterprise Value was at its highest in in the December 2014 quarter at 1.20B. The Enterprise Value was at its lowest in in the June 2021 quarter at -38993670.24.

Tempest Therapeutics, Inc. (TPST) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Tempest Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tempest Therapeutics, Inc. (TPST) Average Enterprise Value

How has TPST Enterprise Value performed in the past?

The current Enterprise Value of Tempest Therapeutics, Inc. (TPST) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Tempest Therapeutics, Inc. (TPST) Enterprise Value vs. Peers

How is TPST’s Enterprise Value compared to its peers?

Tempest Therapeutics, Inc.’s Enterprise Value is greater than Indaptus Therapeutics, Inc. (8.12M), less than Rezolute, Inc. (281.53M), greater than Comera Life Sciences Holdings, Inc. (-913895.00), greater than Forte Biosciences, Inc. (1.13M), less than Sana Biotechnology, Inc. (941.95M), less than Olema Pharmaceuticals, Inc. (675.70M), less than Cullinan Oncology, Inc. (865.26M), less than aTyr Pharma, Inc. (138.44M), less than Zentalis Pharmaceuticals, Inc. (281.53M), less than Lyell Immunopharma, Inc. (236.56M), less than Monte Rosa Therapeutics, Inc. (284.72M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (7.20B), less than ZIVO Bioscience, Inc. (40.97M), greater than RenovoRx, Inc. (14.41M), less than Ikena Oncology, Inc. (47.83M), greater than Catalyst Biosciences, Inc. (19.42M), less than Akari Therapeutics, Plc (38.48M), less than Armata Pharmaceuticals, Inc. (199.34M), less than Anebulo Pharmaceuticals, Inc. (49.05M), greater than Scopus BioPharma Inc. (-357889.00), greater than Processa Pharmaceuticals, Inc. (-892575.00),

Build a custom stock screener for Tempest Therapeutics, Inc. (TPST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tempest Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tempest Therapeutics, Inc. (TPST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tempest Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.